FundaMental Pharma

FundaMental Pharma GmbH (FMP) is developing new types of drugs that act as ‘molecular spacers’ and disrupt a death signaling complex in the brain. Using this pharmacological strategy, FMP scientists succeeded in eliminating the toxic properties of the glutamate-controlled NMDA-type neurotransmitter receptor.

FMP has already identified first drug candidates that are currently in pre-clinical development and will be tested in humans within the next 2-3 years.

The discovery of an entirely new pharmacological principle ('interface targeting') raises hopes that previously untreatable neurodegenerative diseases in humans can be mitigated. Interface inhibitors open up new possibilities, both in terms of drug treatments and gene therapy approaches.

FMP was established in 2016 as a biotech start-up of the Interdisciplinary Center for Neurosciences (IZN) at Heidelberg University by Professor Hilmar Bading, Junior Professor Daniela Mauceri and Dr. Thomas Schulze.

Pressemeldungen

HTGF Investment FundaMental Pharma

FundaMental Pharma Logo
Spacing rules in the brain: Novel compounds that act as molecular spacers in the brain prevent neurodegeneration High-Tech Gründerfonds (HTGF) provides seed funding for the neuro start-up FundaMental Pharma GmbH (FMP), a spin-off of the Interdisciplinary Center for…
Read

Info & Contact

Dr. Thomas Schulze, CEO
Phone:
+49 171 7860209
Web:
www.fundamentalpharma.com

Address

FundaMental Pharma GmbH
Dr. Thomas Schulze, CEO
c/o FundaMental Pharma GmbH
Johann-Fischer-Straße 2, 69121 Heidelberg

In portfolio

04. May 2021